--- title: "U.S. stock market midday update: Sol-Gel Tech surges 19.30% due to enhanced profitability, with significant market capital inflow" type: "News" locale: "en" url: "https://longbridge.com/en/news/281222524.md" description: "Sol-Gel Tech rose 19.30%; Eli Lilly rose 3.11%, with a transaction volume of USD 1.146 billion; Pfizer rose 0.74%, with a transaction volume of USD 597 million; Johnson & Johnson rose 0.57%, with a transaction volume of USD 570 million; AstraZeneca rose 0.85%, with a market capitalization of USD 303 billion" datetime: "2026-03-31T17:03:08.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281222524.md) - [en](https://longbridge.com/en/news/281222524.md) - [zh-HK](https://longbridge.com/zh-HK/news/281222524.md) --- # U.S. stock market midday update: Sol-Gel Tech surges 19.30% due to enhanced profitability, with significant market capital inflow **U.S. Stock Market Midday Update** Sol-Gel Tech rose by 19.30%. Based on recent news, 1. On April 1, Sol-Gel Tech announced a net profit of €200,000 for the year, with revenue of €14.9 million. This financial report indicates an improvement in the company's profitability, driving the stock price up. 2. There have been no other significant news recently. The overall market performance is stable, with noticeable capital inflows. **Stocks with High Trading Volume in the Industry** Eli Lilly rose by 3.11%, with a trading volume of $1.146 billion. Based on recent key news: 1. On March 30, Eli Lilly reached a $2.75 billion cooperation agreement with Insilico Medicine, boosting the stock price. This agreement involves AI drug development, with Eli Lilly obtaining global exclusive rights and Insilico Medicine receiving a $115 million upfront payment. Source: Zhitong Finance 2. On March 31, Eli Lilly announced the acquisition of Centessa Pharmaceuticals for $7.8 billion, enhancing its competitiveness in the new drug market for narcolepsy. This move demonstrates Eli Lilly's proactive positioning in high-growth markets. Source: Investing.com 3. On March 30, the AI pharmaceutical industry is experiencing increased prosperity, and the collaboration between Eli Lilly and Insilico Medicine is seen as a sign of AI drug discovery evolving from research curiosity to commercial reality. Source: Titanium Media Pfizer rose by 0.74%, with a trading volume of $597 million. Based on recent key news: 1. On March 31, Pfizer filed for a new indication in China for the preventive treatment of adult episodic migraines, boosting market confidence. The global sales of Reyvow are expected to reach $1.424 billion by 2025, indicating strong market potential. Source: Zhitong Finance 2. On March 31, Pfizer completed a transitional contract, leading the market to reassess its business value, which pushed the stock price up. Recent trading volume has significantly increased, indicating a rise in bullish market sentiment. Source: Zhitong Finance 3. On March 31, the National Healthcare Security Administration met with Pfizer and other multinational pharmaceutical companies to deepen cooperation, enhance the level of openness, and further smooth communication channels. Source: Jinshi Data Johnson & Johnson rose by 0.57%, with increased trading volume. Based on recent key news: 1. On March 30, Johnson & Johnson signed a $500 million research and development cooperation agreement with Royalty Pharma to advance the development of the JNJ-4804 drug, resulting in a 0.7% increase in stock price. Source: Reuters 2. On March 30, RBC analysts stated that Johnson & Johnson's vision division targets high single-digit long-term growth, enhancing market confidence. Source: RBC 3. On March 29, Johnson & Johnson's ICOTYDE drug performed excellently in clinical trials for treating psoriasis, further boosting market confidence in its product line. Source: RTTNews The pharmaceutical industry is seeing increased R&D investment, intensifying market competition **Stocks Ranked Among the Top by Market Capitalization in the Industry** AstraZeneca rose by 0.85%. Based on recent key news: 1. On March 30, Alibaba Health signed a strategic cooperation agreement with AstraZeneca to promote the development of medical health services in a more professional and sustainable direction. This collaboration combines AstraZeneca's expertise with Alibaba Health's digital outreach capabilities, enhancing market confidence in AstraZeneca and driving up its stock price. 2. On March 30, GSK announced it received a $100 million upfront payment from AstraZeneca to advance the development of innovative oncology therapies. This funding injection boosted market confidence in AstraZeneca's capabilities in the innovative drug sector, leading to an increase in stock price. 3. On March 31, AstraZeneca achieved positive results in a Phase III trial for COPD patients, with its stock price rising by 1.20%. This result strengthened market confidence in its new drug development capabilities. The pharmaceutical industry is active in collaboration and research and development, enhancing market confidence ### Related Stocks - [SLGL.US](https://longbridge.com/en/quote/SLGL.US.md) ## Related News & Research - [Major Investor Quietly Boosts Stake in Sol-Gel Technologies](https://longbridge.com/en/news/292367537.md) - [Opaleye Management reports $124,893 Sol-Gel Technologies share purchase](https://longbridge.com/en/news/292810686.md) - [Opaleye Management reports $38,433 Sol-Gel Technologies share acquisition](https://longbridge.com/en/news/292356488.md) - [Sol-Gel Technologies (SLGL) Initiated with a Buy at Mizuho Securities](https://longbridge.com/en/news/290666760.md) - [Opaleye Management reports $123,073 Sol-Gel common share purchase](https://longbridge.com/en/news/291594731.md)